about
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportVisualization of stress fractures of the foot using PET-MRI: a feasibility study.Meniscal measurements of T1rho and T2 at MR imaging in healthy subjects and patients with osteoarthritis.PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.PET/MR in Oncology: Non-18F-FDG Tracers for Routine Applications.PSMA Ligands for PET-Imaging of Prostate Cancer.Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.[PSMA-radioguided surgery in localised recurrent prostate cancer].Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis.Evaluation of T1ρ as a potential MR biomarker for liver cirrhosis: comparison of healthy control subjects and patients with liver cirrhosis.Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear cause.[PSMA-Radioguided Surgery for Salvage Lymphadenectomy in Recurrent Prostate Cancer].Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.[PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects].Assessment of T1, T1ρ, and T2 values of the ulnocarpal disc in healthy subjects at 3 teslaOne-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate CancerEfficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical ProstatectomyPositron-emission tomography imaging in urological oncology: Current aspects and developmentsSingle Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided SurgeryMatched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical ProstatectomyEarly Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
P50
Q26747480-65F7D58F-B5F4-4039-9748-A8B54808F280Q36402086-4E7C5EA4-E3EF-4443-A331-BBDA4226958BQ37133840-BF717073-7F35-4AD5-BD66-EE1F6C7491F0Q38197981-C13CC702-56E3-4A27-BC7C-A53F8B870915Q38211164-EF3C2C43-A276-4195-AD5E-7C1B22BDEC39Q38661165-D3A0E0FC-D578-4567-8650-C3C0A507A374Q38853977-24CB301D-2EBD-498C-A2F9-9D4A48275ABFQ39930921-5208670F-4453-4B8A-8ECC-E8A702C8B473Q40331189-DF5907E2-56AC-4D94-9247-5BA1D0A8D992Q40468376-6196B99E-39E8-43CD-ADB2-6AE7A0379A41Q40959799-FE35A895-A386-4F7E-B47D-4DF53251FECDQ41038146-F3C3BC73-C607-49FC-B8B1-CA35B04B737FQ46148036-D4B70741-E520-460D-9CFC-4D6BB3607AD0Q47399411-6E8D41F6-1630-4658-94CD-478C7509B0A1Q47710564-1C6816C4-8E96-4B2D-9FBA-D29056DA0F60Q50083626-76032122-B236-43E3-9F0E-36125A10EB4EQ50096215-F40A8D63-E3D6-416A-B2DF-F9BD2DCF7661Q50504575-0117111D-1942-4840-9929-DB56BDF5D0E5Q50975656-4F0C44A3-40D0-42D9-8F72-CA42C0423174Q51100103-AEC6F107-A48C-4255-B9CB-0AA730B819DDQ51713743-BBA1D712-A286-456D-A5C2-B58773649F80Q52601895-FAE6DF22-0A59-48A6-898F-BB2DC6FBAFC6Q53026502-3D5F24B8-2D3B-44AD-9355-6A19C1BE2CCEQ53289215-12445B12-6070-4660-9366-94AAB70F3190Q53385260-4031194E-9F94-4D6D-B8BC-B721D0907D17Q53549289-37F22576-3423-45B9-8CDF-2B5F8D974BE5Q88144718-AFAF696C-7B1D-4F39-A4EB-1635207CF2B1Q88793372-99EB3AB2-A768-42A0-948E-586CA1F11DD8Q89938129-9303B18E-735C-44EA-B89E-5BD814259A2AQ90920386-E007A8C2-73CA-4578-9F9B-6A2753816353Q93108483-7C398D64-8E2E-4AA8-B338-604A307FB7ADQ93115819-D5446F7B-6A46-44F2-AB4F-28A70CC7161DQ93159963-7A4DFE98-15A9-4B45-9D1F-A99C02F0139C
P50
description
investigador
@es
researcher
@en
name
Isabel Rauscher
@en
Isabel Rauscher
@nl
type
label
Isabel Rauscher
@en
Isabel Rauscher
@nl
prefLabel
Isabel Rauscher
@en
Isabel Rauscher
@nl
P31
P496
0000-0003-4655-2153